The phase Ia clinical trial is designed to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. The study will be conducted in Europe.
Preclinical research conducted on the clinical candidate demonstrated favorable characteristics in potency, cross-resistance profiles and pharmacokinetic properties, supporting the exploration of oral dosing in the clinical trials.
“As there is a great need of new and effective treatment for chronic hepatitis C, we are extremely pleased that this project with joint resources and efforts now enters clinical trials,” said Medivir's CEO Lars Adlersson.
The hepatitis C virus market is currently dominated by interferon-based treatments.